When was RayzeBio founded?

RayzeBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is RayzeBio located?

RayzeBio is headquartered in San Diego, United States.

How many employees does RayzeBio have?

As of Sep 30, 2026, the latest employee count at RayzeBio is 288.

Is RayzeBio a funded company?

RayzeBio is a funded company, having raised a total of $426M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 05, 2020.

How much is RayzeBio worth?

The last known valuation of RayzeBio was $***** as of Sep 11, 2023.

When was the latest funding round of RayzeBio?

RayzeBio's latest funding was a $***** Series D round on Aug 25, 2022, with participation from 7 investors.

Where does RayzeBio rank among its competitors?

RayzeBio ranks 17th amongst 2563 active competitors, of which 869 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of RayzeBio?

RayzeBio's top competitors include Jazz Pharmaceuticals, Syndax and Immuneel. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

RayzeBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Website: rayzebio.com
Email ID: *****@rayzebio.com
Part Of

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Acquired

Total Funding

$426M in 4 rounds

Latest Funding Round

Series D, Aug 25, 2022, $*****

Last Known Valuation

$***** as on Sep 11, 2023

Investors

Venrock & 23 more

Ranked

17^th among 2563 active competitors

Employee Count

288 as on Sep 30, 2026

Investment & Acquisitions

RayzeBio

Similar Companies

Molecular Partners & 108 more

Exit Details

Acquired by Bristol-Myers Squibb (Dec 26, 2023)

View RayzeBio's full profile

RayzeBio got acquired by Bristol-Myers Squibb on Dec 26, 2023 at an acquisition amount of $*****.

Click here to take a look at RayzeBio's acquisition in detail

RayzeBio has raised a total funding of $426M over 4 rounds. Its first funding round was on Aug 05, 2020. Its latest funding round was a Series D round on Aug 25, 2022 for $*****. 7 investors participated in its latest round. RayzeBio has 24 institutional investors.

Here is the list of recent funding rounds of RayzeBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2022	9079431	Series D	5515065	9563245	3080649	5804667
Jun 08, 2021	7411766	Series C	2721897	9626816	2597913	Perceptive Advisors & 13 more
Nov 23, 2020	8283344	Series B	2344099	4055285	Venrock	Orbimed & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of RayzeBio's funding rounds and investors

The founders of RayzeBio is Deborah Charych.

Here are the details of RayzeBio's key team members:

Deborah Charych: Co-Founder & Chief Technology Officer of RayzeBio.

View details of RayzeBio's Founder profiles and Board Members

RayzeBio's employee count trend

RayzeBio has 288 employees as of Sep 26. Here is RayzeBio's employee count trend over the years:

Uncover RayzeBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RayzeBio include Jazz Pharmaceuticals, Syndax and Immuneel. Here is the list of Top 10 competitors of RayzeBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
3rd	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
7th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
8th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
17th	RayzeBio 2019, San Diego (United States), Acquired	R&D company focused on manufacturing of cancer drugs	$426M	Venrock, Perceptive Advisors & 22 others	70/100